IL-1R9 Inhibitors

IL-1R9, or IL-1RL2, belongs to the family of interleukin-1 receptors which play pivotal roles in inflammatory responses. The group of compounds titled IL-1R9 Inhibitors encompasses agents that can influence the functionality of IL-1R9 by either directly targeting it or its related signaling cascades.

Ruxolitinib and Tofacitinib are both JAK inhibitors which interrupt the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, a downstream signaling route of several IL-1 receptors. BAY 11-7082 and Parthenolide are both inhibitors of NF-kB activation, a common end-point in the IL-1 signaling cascade. Such inhibitors halt inflammatory responses that could be initiated or amplified by IL-1R9. SB202190, PD98059, and U0126 focus on the MAP kinase pathway which is essential for IL-1-mediated responses. Specifically, they inhibit p38 MAP kinase and MEK, respectively. Similarly, SP600125, a JNK inhibitor, targets the MAP kinase activation induced by IL-1. LY294002 and Wortmannin, both PI3K inhibitors, hold the potential to impact several signaling pathways related to IL-1R9, especially those involving Akt and mTOR. sc-514 is an IKK-2 inhibitor that directly affects the NF-kB activation pathway, another common signaling route associated with IL-1 receptors.